Genmab 2025 Net Profit Falls, Revenue Increases; 2026 Revenue Outlook Issued

MT Newswires Live

Feb 18

Genmab (GMAB) reported a 2025 net profit Tuesday of $15.37 per diluted share, down from $17.53 a year earlier.

Analysts polled by FactSet expected $18.48.

Revenue for the 12 months ended Dec. 31 was $3.72 billion, compared with $3.12 billion a year earlier.

Analysts surveyed by FactSet expected $3.70 billion.

For 2026, the company expects revenue in the range of $4.07 billion to $4.40 billion. Analysts polled by FactSet estimate $4.32 billion.

Shares of the company were up 1.5% in recent Tuesday trading.

Price: 30.53, Change: +0.50, Percent Change: +1.67

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612792466"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612792466\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612792466?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-18 00:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612792466","market":"fut","top_or_hot":-1,"title":"Genmab 2025 Net Profit Falls, Revenue Increases; 2026 Revenue Outlook Issued","media":"MT Newswires Live","content":"<html><body><p> Genmab (GMAB) reported a 2025 net profit Tuesday of $15.37 per diluted share, down from $17.53 a year earlier.</p><p>Analysts polled by FactSet expected $18.48.</p><p>Revenue for the 12 months ended Dec. 31 was $3.72 billion, compared with $3.12 billion a year earlier.</p><p>Analysts surveyed by FactSet expected $3.70 billion.</p><p>For 2026, the company expects revenue in the range of $4.07 billion to $4.40 billion. Analysts polled by FactSet estimate $4.32 billion.</p><p>Shares of the company were up 1.5% in recent Tuesday trading.</p><p>Price: 30.53, Change: +0.50, Percent Change: +1.67</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genmab 2025 Net Profit Falls, Revenue Increases; 2026 Revenue Outlook Issued</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenmab 2025 Net Profit Falls, Revenue Increases; 2026 Revenue Outlook Issued\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-18 00:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Genmab (GMAB) reported a 2025 net profit Tuesday of $15.37 per diluted share, down from $17.53 a year earlier.</p><p>Analysts polled by FactSet expected $18.48.</p><p>Revenue for the 12 months ended Dec. 31 was $3.72 billion, compared with $3.12 billion a year earlier.</p><p>Analysts surveyed by FactSet expected $3.70 billion.</p><p>For 2026, the company expects revenue in the range of $4.07 billion to $4.40 billion. Analysts polled by FactSet estimate $4.32 billion.</p><p>Shares of the company were up 1.5% in recent Tuesday trading.</p><p>Price: 30.53, Change: +0.50, Percent Change: +1.67</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2612792466","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612792466","pubTimestamp":1771347465,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Genmab  reported a 2025 net profit Tuesday of $15.37 per diluted share, down from $17.53 a year earlier.Analysts polled by FactSet expected $18.48.Revenue for the 12 months ended Dec. 31 was $3.72 billion, compared with $3.12 billion a year earlier.Analysts surveyed by FactSet expected $3.70 billion.For 2026, the company expects revenue in the range of $4.07 billion to $4.40 billion. Analysts polled by FactSet estimate $4.32 billion.Shares of the company were up 1.5% in recent Tuesday trading.Price: 30.53, Change: +0.50, Percent Change: +1.67","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GMAB":"Genmab A/S"},"translate_title":"Genmab 2025净利润下降，营收增长；发布2026年收入展望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GMAB":1},"content_text":"Genmab (GMAB) reported a 2025 net profit Tuesday of $15.37 per diluted share, down from $17.53 a year earlier.Analysts polled by FactSet expected $18.48.Revenue for the 12 months ended Dec. 31 was $3.72 billion, compared with $3.12 billion a year earlier.Analysts surveyed by FactSet expected $3.70 billion.For 2026, the company expects revenue in the range of $4.07 billion to $4.40 billion. Analysts polled by FactSet estimate $4.32 billion.Shares of the company were up 1.5% in recent Tuesday trading.Price: 30.53, Change: +0.50, Percent Change: +1.67","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}